REG - BSF Enterprise PLC - Results of Annual General Meeting

BSF EnterpriseAnnouncement

12/07/2022 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220712:nRSL1936Sa&default-theme=true

RNS Number : 1936S  BSF Enterprise PLC  12 July 2022

12 July 2022

 

BSF Enterprise plc

("BSF" or the "Company")

 

Results of Annual General Meeting

 

BSF Enterprise plc (LSE: BSFA),  is pleased to announce that at the Company's
Annual General Meeting held earlier today, all resolutions proposed were duly
passed by shareholders by way of a poll, the results of which were as follows:

 

 Resolution      Poll Results
         For     Against                 Abstain  Discretionary  Total
 1       Shares  43,864,905              -        -              -      ‎43,864,905‎
         %       100                     -        -              -      100
 2       Shares  ‎43,864,905‎            -        -              -      ‎‎43,864,905‎‎
         %       100                     -        -              -      100
 3       Shares  ‎43,864,905‎            -        -              -      ‎‎43,864,905‎‎
         %       100                     -        -              -      100
 4       Shares  ‎43,864,905‎            -        -              -      ‎‎43,864,905‎‎
         %       100                     -        -              -      100
 5       Shares  ‎‎43,864,905‎‎          -        -              -      ‎‎43,864,905‎‎
         %       100                     -        -              -      100
 6       Shares  ‎‎43,864,905‎‎          -        -              -      ‎‎43,864,905‎‎
         %       100                     -        -              -      100
 7       Shares  ‎‎43,864,905‎‎          -        -              -      ‎‎43,864,905‎‎
         %       100                     -        -              -      100

 

The total number of ordinary shares in issue on 12 July 2022 was
‎85,783,409‎‎ ‎ shares. Of the ordinary shares in issue,
‎7,798,491‎ shares have been issued as restricted shares under the
Company's ‎Restricted Share Plan or under agreements containing equivalent
terms, are subject to voting restrictions and ‎were restricted from being
voted at the meeting.‎  56.25% of voting capital entitled to vote at the
meeting was instructed in respect of the resolutions put to the Annual General
Meeting.

 

The full text of the resolutions can be found in the Notice of Annual General
Meeting dated 17 June 2022, which is ‎available on the Company's website
at:‎ https://bsfenterprise.com/documents/
(https://bsfenterprise.com/documents/)

 

In accordance with the FCA's Listing Rule 9.6.2, copies of all the
‎resolutions passed by the Company's shareholders, other than ordinary
business will be ‎submitted to the National Storage Mechanism and will
shortly be available for ‎inspection at

https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com) or contact:

 BSF Enterprise PLC                        Via SEC Newgate below
 Geoff Baker - Non-Executive Director

 Graham Duncan - Chief Financial Officer

 Shard Capital (Broker)
 Damon Heath                               020 7186 9952

 Erik Woolgar

 SEC Newgate (Financial Communications)
 Bob Huxford                               020 3757 6882

 Elisabeth Cowell                          BSF@secnewgate.co.uk

 George Esmond

‎LEI: ‎‎2138007PJT69H8FYLC06‎

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people. Building on this success, it aims to
produce the UK's first high quality lab-grown meat from its laboratory in
Newcastle the next 12 months, transforming the meat-production industry
towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to acquire a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGUURARUUUBAAR